Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: NRM004
MIFTS: 52

Neuroma

Categories: Cancer diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Neuroma

About this section

MalaCards integrated aliases for Neuroma:

Name: Neuroma 12 56 45 15 17 74

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2001
MeSH 45 D009463
NCIt 51 C3275
SNOMED-CT 69 25169009
UMLS 74 C0027858
Sources

Summaries for Neuroma

About this section
Disease Ontology : 12 A nervous system benign neoplasm that is characterized as a nerve tissue tumor.

MalaCards based summary : Neuroma is related to acoustic neuroma and multiple mucosal neuroma. An important gene associated with Neuroma is ANK3 (Ankyrin 3), and among its related pathways/superpathways are Signaling by GPCR and Developmental Biology. The drugs Bupivacaine and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and testes, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 77 A neuroma (/njʊəˈroʊmə/; plural: neuromata or neuromas) is a growth or tumor of nerve tissue. Neuromas... more...

Sources

Related Diseases for Neuroma

About this section

Diseases related to Neuroma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 279)
# Related Disease Score Top Affiliating Genes
1 acoustic neuroma 34.0 BICRA NF1 NF2 TGFB1
2 multiple mucosal neuroma 33.7 ENO2 RET
3 neurofibromatosis, type iv, of riccardi 32.9 NF1 NF2 RET
4 multiple endocrine neoplasia, type iib 32.7 CALCA GDNF RET
5 hydrocephalus 30.4 ENO2 GFAP NGF TGFB1
6 neurofibroma 30.3 NF1 NF2 S100B
7 hemangioma 30.0 ENO2 FGF2 RET
8 thyroid carcinoma, familial medullary 29.9 CALCA ENO2 GDNF RET
9 ependymoma 29.9 ENO2 GFAP NF2 S100B
10 plexiform neurofibroma 29.8 ANK3 NF1 NF2
11 malignant peripheral nerve sheath tumor 29.8 NF1 NF2 S100B
12 neurilemmoma 29.8 ENO2 GFAP NF1 NF2 S100B
13 neurofibrosarcoma 29.7 NF1 NF2
14 multiple endocrine neoplasia 29.7 CALCA GDNF NF1 RET
15 pheochromocytoma 29.1 CALCA ENO2 GDNF NF1 NGF RET
16 neuroma biliary tract 12.1
17 neurofibromatosis, type ii 11.5
18 neurofibromatosis, type i 11.2
19 klumpke paralysis 11.1
20 erb-duchenne and dejerine-klumpke palsies 11.1
21 cerebral convexity meningioma 10.4 GFAP NF2
22 meningothelial meningioma 10.4 ENO2 NF2
23 intraventricular meningioma 10.4 GFAP NF2
24 primitive neuroectodermal tumor of the cervix uteri 10.4 ENO2 GFAP
25 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.4
26 melanotic medulloblastoma 10.4 ENO2 GFAP
27 bednar tumor 10.4 ENO2 S100B
28 rhabdoid meningioma 10.4 GFAP NF2
29 gemistocytic astrocytoma 10.4 GFAP S100B
30 cerebellar medulloblastoma 10.4 ENO2 GFAP
31 fibrous meningioma 10.4 NF2 S100B
32 syringocystadenoma papilliferum 10.4 GFAP S100B
33 ossifying fibromyxoid tumor 10.4 ENO2 S100B
34 central nervous system primitive neuroectodermal neoplasm 10.4 ENO2 GFAP
35 clear cell ependymoma 10.4 ENO2 GFAP
36 chordoid meningioma 10.4 GFAP S100B
37 spinal cancer 10.4 GFAP NF2
38 askin's tumor 10.4 ENO2 NGF
39 dysembryoplastic neuroepithelial tumor 10.4 GFAP S100B
40 spindle cell rhabdomyosarcoma 10.4 GFAP S100B
41 lesion of sciatic nerve 10.4 NGF SCN10A
42 benign ependymoma 10.4 ENO2 GFAP NF2
43 middle cerebral artery infarction 10.4 ENO2 S100B
44 subependymal glioma 10.3 ENO2 GFAP
45 chordoid glioma 10.3 GFAP NF2 S100B
46 intracranial cysts 10.3 ENO2 GFAP S100B
47 anaplastic ependymoma 10.3 GFAP NF2 S100B
48 astroblastoma 10.3 ENO2 GFAP
49 pineocytoma 10.3 ENO2 GFAP S100B
50 myxopapillary ependymoma 10.3 GFAP S100B

Graphical network of the top 20 diseases related to Neuroma:



Diseases related to Neuroma
Sources

Symptoms & Phenotypes for Neuroma

About this section

MGI Mouse Phenotypes related to Neuroma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.27 ANK3 ENO2 FGF2 GDNF GFAP NF1
2 cardiovascular system MP:0005385 10.13 ACTA2 FGF2 GDNF GFAP NF1 NGF
3 mortality/aging MP:0010768 10.11 ANK3 FGF2 GDNF GFAP NF1 NF2
4 growth/size/body region MP:0005378 10.1 ENO2 GDNF GFAP NF1 NF2 NGF
5 muscle MP:0005369 9.97 ACTA2 FGF2 GDNF GFAP NF1 NGF
6 nervous system MP:0003631 9.97 ANK3 ENO2 FGF2 GDNF GFAP NF1
7 neoplasm MP:0002006 9.73 FGF2 NF1 NF2 NRP1 RET TGFB1
8 respiratory system MP:0005388 9.5 ANK3 ENO2 NF1 NF2 RET SCN10A
9 vision/eye MP:0005391 9.28 ACTA2 FGF2 GFAP NF1 NF2 NGF
Sources

Drugs & Therapeutics for Neuroma

About this section

Drugs for Neuroma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupivacaine Approved, Investigational Phase 4,Not Applicable 2180-92-9, 38396-39-3 2474
2
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
3
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
4 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
5 Gentamicins Phase 4,Not Applicable
6 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Anesthetics Phase 4,Phase 1,Not Applicable,Early Phase 1
8 Anesthetics, Local Phase 4,Phase 1,Not Applicable,Early Phase 1
9 Central Nervous System Depressants Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Anti-Inflammatory Agents Phase 4,Phase 2,Not Applicable
12 Hormones Phase 4,Not Applicable
13 Hormone Antagonists Phase 4,Not Applicable
14 glucocorticoids Phase 4,Not Applicable
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Not Applicable
16 Immunosuppressive Agents Phase 4,Phase 2,Phase 1,Early Phase 1
17 Immunologic Factors Phase 4,Phase 2,Phase 1,Early Phase 1
18 Triamcinolone hexacetonide Phase 4
19 Triamcinolone diacetate Phase 4
20 triamcinolone acetonide Phase 4
21
Capsaicin Approved Phase 2,Phase 1 404-86-4 1548943
22
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
23
Mexiletine Approved, Investigational Phase 2 31828-71-4 4178
24
Morphine Approved, Investigational Phase 2 57-27-2 5288826
25
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 46835353 6436030 5284616
26
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
27
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177 70789204
28
Acetylcholine Approved, Investigational Phase 2,Not Applicable 51-84-3 187
29
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
30
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
31
Lapatinib Approved March 2007, Investigational Phase 2,Early Phase 1 388082-78-8, 231277-92-2 208908 9941095
32
Lactitol Investigational Phase 2 585-86-4, 585-88-6 493591
33 Antibodies Phase 2,Phase 1
34 Angiogenesis Modulating Agents Phase 2,Phase 1
35 Angiogenesis Inhibitors Phase 2,Phase 1
36 Immunoglobulins Phase 2,Phase 1
37 Antineoplastic Agents, Immunological Phase 2,Phase 1
38 Antibodies, Monoclonal Phase 2,Phase 1
39 Protein Kinase Inhibitors Phase 2,Early Phase 1
40 Analgesics, Opioid Phase 2
41 Anti-Arrhythmia Agents Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Sodium Channel Blockers Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Narcotics Phase 2
44 Analgesics Phase 2,Not Applicable
45 Diuretics, Potassium Sparing Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Endostatins Phase 2 71581480
47 Antibiotics, Antitubercular Phase 2,Phase 1,Early Phase 1
48 Antifungal Agents Phase 2,Phase 1,Early Phase 1
49 Neurotransmitter Agents Phase 2,Phase 1,Not Applicable
50 Acetylcholine Release Inhibitors Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 122)
# Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Unknown status NCT02379754 Phase 4 Gentamicins
2 Pathophysiology of Post Amputation Pain Completed NCT01632709 Phase 4 Bupivacaine;Placebo
3 A Comparative Post-marketing Study of Commercially Available Peripheral Nerve Gap Repair Options Completed NCT00948025 Phase 4
4 Blind and Ultrasound Guided Injection in Morton Neuroma Recruiting NCT03046108 Phase 4 blind injection of Mepivacaine;blind injection of Triamcinolone;guided injection of mepivacaine;guided injection of Triamcinolone
5 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
6 Intranasal Neurostimulation in Ameliorating Symptoms of Neuropathic Corneal Pain Recruiting NCT03674892 Phase 4
7 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
8 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
9 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Unknown status NCT02934256 Phase 2 Icotinib
10 A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) Completed NCT02283957 Phase 2 CNTX-4975
11 ALGRX 4975 in the Treatment of Patients With Morton's Neuroma Completed NCT00130962 Phase 2 ALGRX 4975
12 A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) Completed NCT02678793 Phase 2 CNTX-4975
13 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
14 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
15 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
16 Efficacy of Opioids and Mexiletine for the Treatment of Postamputation Pain Completed NCT00383682 Phase 2 morphine and mexiletine
17 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
18 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
19 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
20 RGD PET/MRI in Sporadic Vestibular Schwannoma Recruiting NCT03393689 Phase 2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2
21 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
22 Study of Aspirin in Patients With Vestibular Schwannoma Recruiting NCT03079999 Phase 2 Aspirin;Placebo
23 Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Recruiting NCT03231306 Phase 2 Binimetinib
24 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
25 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Active, not recruiting NCT01345136 Phase 2 RAD001, everolimus
26 Axillary Reverse Mapping Active, not recruiting NCT00572481 Phase 2
27 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting NCT02831257 Phase 2 AZD2014
28 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT02129647 Phase 2 Axitinib
29 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2 Bevacizumab
30 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
31 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
32 PTC299 for Treatment of Neurofibromatosis Type 2 Terminated NCT00911248 Phase 2 PTC299
33 Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma Terminated NCT02988726 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
34 Botulinum Toxin Type A for Neuroma Pain Withdrawn NCT01374191 Phase 2 onabotulinum toxin type-A;2nd phase - onabotulinum toxin type-A
35 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Withdrawn NCT02986919 Phase 2 CPI-0610
36 Compare Ultrasound Assisted Cold Therapy and Lidocaine Injection to Treat Morton's Neuroma Completed NCT02838758 Phase 1 Lidocaine;Saline
37 Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma) Completed NCT02550756 Phase 1 CTNX-4975
38 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
39 EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Completed NCT00056199 Phase 1 EYE001
40 An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors Completed NCT00030043 Phase 1
41 Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
42 Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET Recruiting NCT03542773 Phase 1 18F-DCFPyL Injection
43 Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma Suspended NCT01083966 Phase 1 Bevacizumab (Avastin)
44 Morton's Neuroma: Manipulation Versus Steroid Injection Unknown status NCT02304094 Not Applicable methylprednisolone
45 Comparison of Alcohol and Steroid Injection for Treating Morton's Neuroma Unknown status NCT00284583 Not Applicable Injection of Steroid into Foot;Injection of Alcohol into Foot;Injection of Lidocaine into Foot
46 Neuroma Injections to Treat Restless Legs Syndrome - RCT Unknown status NCT00656110 Not Applicable equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml;Normal saline - 1ml
47 Effect of Implant Position on Magnetic Resonance Image Distortion Unknown status NCT02246231 Not Applicable
48 Response Prediction After GKS in Patients With Vestibular Schwannoma Using DCE MR Imaging Unknown status NCT03097822
49 Preoperative Vestibular Rehabilitation Effectiveness After Vestibular Schwannoma Surgery Unknown status NCT02275325 Not Applicable
50 Vestibular Schwannoma and Psychological Factors Unknown status NCT01743248

Search NIH Clinical Center for Neuroma

Cochrane evidence based reviews: neuroma

Sources

Genetic Tests for Neuroma

About this section
Sources

Anatomical Context for Neuroma

About this section

MalaCards organs/tissues related to Neuroma:

42
Brain, Bone, Testes, Skin, Liver, Thyroid, Breast
Sources

Publications for Neuroma

About this section

Articles related to Neuroma:

(show top 50) (show all 2257)
# Title Authors Year
1
Spontaneous Shrinkage of Cystic Acoustic Neuroma: A Case Report. ( 30685372 )
2019
2
Influence of Selection Bias in Survey Studies Derived From a Patient-Focused Organization: A Comparison of Response Data From a Single Tertiary Care Center and the Acoustic Neuroma Association. ( 30807524 )
2019
3
Influence of Selection Bias in Survey Studies Derived From a Patient-Focused Organization: A Comparison of Response Data From a Single Tertiary Care Center and the Acoustic Neuroma Association. ( 30870367 )
2019
4
Vestibular Traumatic Neuroma Following Temporal Bone Fracture. ( 30531646 )
2019
5
Etiology and Treatment Outcomes for Sural Neuroma. ( 30712380 )
2019
6
An aligned nanofiber nerve conduit that inhibits painful traumatic neuroma formation through regulation of the RhoA/ROCK signaling pathway. ( 30717043 )
2019
7
Targeted Muscle Reinnervation for Prosthesis Optimization and Neuroma Management in the Setting of Transradial Amputation. ( 30733097 )
2019
8
Morton's interdigital neuroma: instructional review. ( 30800476 )
2019
9
The effectiveness of non-surgical interventions for common plantar digital compressive neuropathy (Morton's neuroma): a systematic review and meta-analysis. ( 30809275 )
2019
10
Palisaded Encapsulated (Solitary Circumscribed) Neuroma: A Review of 30 Cases. ( 30834800 )
2019
11
Nerve capping technique with nerve conduit for treating painful digital neuroma: A case report. ( 30853276 )
2019
12
Diagnostic Criteria for Symptomatic Neuroma. ( 30855369 )
2019
13
Surgery for Symptomatic Neuroma: Anatomic Distribution and Predictors of Secondary Surgery. ( 30907815 )
2019
14
Effect of Nerve-Cutting Technique on Nerve Microstructure and Neuroma Formation. ( 30911209 )
2019
15
Risk of posterior semicircular canal trauma when using a retrosigmoid approach for acoustic neuroma surgery and role of endoscopy: An imaging study. ( 29493720 )
2018
16
Painful Terminal Neuroma Prevention by Capping PRGD/PDLLA Conduit in Rat Sciatic Nerves. ( 29938170 )
2018
17
Acoustic Neuroma Treated with Stereotactic Radiosurgery: Follow-up of 335 Patients. ( 29715569 )
2018
18
Mechanical Metatarsalgia as a Risk Factor for Relapse of Morton's Neuroma After Ultrasound-Guided Alcohol Injection. ( 29779991 )
2018
19
Patient Decision Making in Vestibular Schwannoma: A Survey of the Acoustic Neuroma Association. ( 29436268 )
2018
20
Superficial Peroneal Nerve to Deep Peroneal Nerve Transfer With Allograft Conduit for Neuroma in Continuity. ( 29685562 )
2018
21
Nonspecific Chronic Anteromedial Knee Pain Neuroma as a Cause of Infrapatellar Pain Syndrome: Case Study and Literature Review. ( 29404377 )
2018
22
Solitary Circumscribed Neuroma: Dermoscopic clues to facilitate diagnosis. ( 29666696 )
2018
23
Increased sensibility to acute acoustic and blast trauma among patients with acoustic neuroma. ( 29184217 )
2018
24
Risk factors and the associated cutoff values for failure of corticosteroid injection in treatment of Morton's neuroma. ( 29230531 )
2018
25
Plantar Pressure Measurements and Geometric Analysis of Patients With and Without Morton's Neuroma. ( 29641258 )
2018
26
Cochlea-sparing acoustic neuroma treatment with 4I8 radiation therapy. ( 29904732 )
2018
27
Increased Hospital Surgical Volume Reduces Rate of 30- and 90-Day Readmission After Acoustic Neuroma Surgery. ( 29889284 )
2018
28
Acoustic neuroma quality of life: are we missing the point? ( 29948270 )
2018
29
The medium and long-term effect of electrophysiologic monitoring on the facial nerve function in minimally invasive surgery treating acoustic neuroma. ( 29563978 )
2018
30
Epithelial sheath neuroma with extension to the subcutis. ( 29797343 )
2018
31
Long-term outcome after Gamma Knife radiosurgery for acoustic neuroma of all Koos grades: a single-center study. ( 29498575 )
2018
32
Painful Neuroma Treatment of the Supraorbital Nerve and Forehead Neurotization Using Human Cadaveric Nerve Allograft. ( 29521743 )
2018
33
Neuroma Implantation into Long Bones: Clinical Foundation for a Novel Osseointegrated Peripheral Nerve Interface. ( 29922565 )
2018
34
Ophthalmic Complications Following Acoustic Neuroma Resection. ( 29253289 )
2018
35
Endobronchial Mucosal Neuroma with Sarcoidosis. ( 29394980 )
2018
36
The impact of acoustic neuroma on long-term quality-of-life outcomes in the United Kingdom. ( 29330600 )
2018
37
Bilateral Nonsynchronous Pacinian Corpuscle Neuroma. ( 29627280 )
2018
38
Regenerative Peripheral Nerve Interface for Management of Postamputation Neuroma. ( 29847613 )
2018
39
Novel experimental surgical strategy to prevent traumatic neuroma formation by combining a 3D-printed Y-tube with an autograft. ( 29424651 )
2018
40
Analysis of regeneration- and myelination-associated proteins in human neuroma in continuity and discontinuity. ( 29656327 )
2018
41
Incidence and associations of painful neuroma in a contemporary cohort of lower-limb amputees. ( 29654613 )
2018
42
Transcanal Transpromontorial Acoustic Neuroma Surgery: Results and Facial Nerve Outcomes. ( 29227438 )
2018
43
Patterns of stereotactic radiotherapy utilization and fractionation for acoustic neuroma in the United States. ( 29988251 )
2018
44
Trough-Shaped Audiograms Are Common in Patients with Acoustic Neuroma and Sudden Sensorineural Hearing Loss. ( 30021194 )
2018
45
Pearls for the middle fossa approach in acoustic neuroma surgery. ( 30024419 )
2018
46
Topical insulin in neurotrophic keratopathy after resection of acoustic neuroma. ( 30025986 )
2018
47
Electrical stimulation-based nerve location prediction for cranial nerve VII localization in acoustic neuroma surgery. ( 30106250 )
2018
48
Non-contrast magnetic resonance imaging for monitoring patients with acoustic neuroma. ( 30117408 )
2018
49
Perioperative Care of the Patient With Acoustic Neuroma. ( 30117553 )
2018
50
Multi-option therapy vs observation for small acoustic neuroma: hearing-focused management. ( 30197430 )
2018
Sources

Variations for Neuroma

About this section
Sources

Expression for Neuroma

About this section
Search GEO for disease gene expression data for Neuroma.
Sources

Pathways for Neuroma

About this section

Pathways related to Neuroma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 67
Show member pathways
 13.76 CALCA FGF2 GDNF GFAP NF1 NF2
2
Developmental Biology 67
Show member pathways
 12.97 ANK3 FGF2 GDNF NF1 NRP1 RET
3
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 11.88 FGF2 NGF NRP1 TGFB1
4
Neuroscience 4
11.86 CALCA ENO2 GFAP NF1 NF2 NGF
5
L1CAM interactions 67
Show member pathways
 11.71 ANK3 NRP1 SCN10A
6
Spinal Cord Injury 1
11.66 GDNF GFAP TGFB1
7
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.25 FGF2 GDNF GFAP NGF S100B
8
Lung fibrosis 1
11.23 CALCA FGF2 TGFB1
Sources

GO Terms for Neuroma

About this section

Cellular components related to Neuroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 CALCA FGF2 GDNF NGF NRP1 S100B
2 extracellular space GO:0005615 9.81 ACTA2 CALCA ENO2 FGF2 NGF NRP1
3 cell body GO:0044297 9.5 ACTA2 GFAP NF2
4 neuronal cell body GO:0043025 9.43 CALCA ENO2 NRP1 RET S100B TGFB1
5 neurofilament GO:0005883 9.26 GFAP NRP1
6 axon GO:0030424 9.23 ANK3 CALCA NF1 NGF NRP1 RET

Biological processes related to Neuroma according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.96 NF1 NGF S100B TGFB1
2 regulation of signaling receptor activity GO:0010469 9.96 CALCA FGF2 GDNF NGF TGFB1
3 positive regulation of gene expression GO:0010628 9.91 ACTA2 ANK3 NGF RET TGFB1
4 axon guidance GO:0007411 9.87 GDNF NRP1 RET SEMA3F
5 wound healing GO:0042060 9.82 FGF2 NF1 TGFB1
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.79 FGF2 NRP1 TGFB1
7 response to wounding GO:0009611 9.78 GFAP NRP1 TGFB1
8 positive regulation of endothelial cell proliferation GO:0001938 9.76 FGF2 NF1 NRP1
9 response to pain GO:0048265 9.67 CALCA RET
10 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.66 GDNF TGFB1
11 hyaluronan catabolic process GO:0030214 9.65 FGF2 TGFB1
12 negative regulation of cell-cell adhesion GO:0022408 9.65 NF2 TGFB1
13 neural crest cell migration GO:0001755 9.65 GDNF RET SEMA3F
14 lens fiber cell differentiation GO:0070306 9.64 NF2 TGFB1
15 commissural neuron axon guidance GO:0071679 9.63 GDNF NRP1
16 enteric nervous system development GO:0048484 9.63 GDNF RET
17 semaphorin-plexin signaling pathway involved in axon guidance GO:1902287 9.62 NRP1 SEMA3F
18 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 9.62 NF1 RET
19 facial nerve structural organization GO:0021612 9.6 NRP1 SEMA3F
20 sympathetic ganglion development GO:0061549 9.59 NRP1 SEMA3F
21 axon extension involved in axon guidance GO:0048846 9.58 NRP1 SEMA3F
22 branchiomotor neuron axon guidance GO:0021785 9.55 NRP1 SEMA3F
23 MAPK cascade GO:0000165 9.55 FGF2 GDNF NF1 RET TGFB1
24 negative regulation of neuroblast proliferation GO:0007406 9.54 NF1 TGFB1
25 neural crest cell migration involved in autonomic nervous system development GO:1901166 9.52 NRP1 SEMA3F
26 ureteric bud development GO:0001657 9.5 GDNF RET TGFB1
27 trigeminal nerve structural organization GO:0021637 9.49 NRP1 SEMA3F
28 semaphorin-plexin signaling pathway involved in neuron projection guidance GO:1902285 9.46 NRP1 SEMA3F
29 sympathetic neuron projection extension GO:0097490 9.43 NRP1 SEMA3F
30 peripheral nervous system development GO:0007422 9.43 GDNF NF1 NGF
31 sympathetic neuron projection guidance GO:0097491 9.4 NRP1 SEMA3F
32 ventral trunk neural crest cell migration GO:0036486 9.37 NRP1 SEMA3F
33 sympathetic nervous system development GO:0048485 9.13 GDNF NF1 NRP1
34 nerve development GO:0021675 8.8 NGF NRP1 SEMA3F
35 positive regulation of transcription, DNA-templated GO:0045893 10.04 ACTA2 BICRA FGF2 RET TGFB1

Molecular functions related to Neuroma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.13 FGF2 GDNF RET
2 growth factor activity GO:0008083 8.92 FGF2 GDNF NGF TGFB1
Sources

Sources for Neuroma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....